7505 Background: A randomized phase II-III trial was designed to assess efficacy and safety of adding bevacizumab (Bev) to first-line standard chemotherapy (CT) in extensive small-cell lung cancer (SCLC). Methods: Patients with SCLC were enrolled and then received two induction cycles of CT, three weeks apart (cisplatin - etoposide, or cisplatin - cyclophosphamide - epidoxorubicin - etoposide [PCDE]). Responders were randomly assigned 1:1 to receive 4 additional cycles of CT alone or CT plus Bev (7.5 mg/kg) followed by single-agent Bev until progression or unacceptable toxicity. The primary endpoint was response rate (RR) after 4 cycles (i.e. two cycles after randomization). Results: 147 patients were enrolled. After the 2 first CT cycles, RR was observed in 99 patients (67.3%) and among them, 74 patients were eligible for Bev and randomly assigned to CT only (n = 37) or CT plus Bev (n = 37). Median number of CT was 6 in CT alone group and 6 in CT plus Bev group. The median number of additional Bev administrations in the latter group was 4. The percentage of still-responder patients after 4 cycles, including 2 with bevacizumab in the experimental arm, did not differ between the CT arm (89.2%) and the CT+bevacizumab arm (91.9%). Neither progression-free survival (PFS) nor overall survival (OS) significantly differed (median PFS : 5.5 and 5.3 months; median OS: 13.0 and 11.1 months, in CT alone and CT plus Bev groups respectively). In the CT alone group and the CT plus Bev group, 22 (59.5%) versus 23 (62.2%) of patients respectively, experienced one or more grade 3-4 adverse events. Specific Bev-induced toxicity was observed in 15 (40.5%) patients; one unexpected toxicity (fatal subdural hematoma) was reported in the combination group. Evaluation of serum biomarkers will be presented. Conclusions: Bev did not increase the proportion of responder patients at cycle 4. This phase II study failed to demonstrate any signal suggesting an outcome improvement in extensive-SCLC. Consequently this trial will not go further the phase 3 part of the program. Clinical trial information: NCT00930891.
1 April 2018 in Le Pharmacien Hospitalier et Clinicien
The current issue of the European Journal of Cardio-Thoracic Surgery includes the worth-reading work of Beattie and associates [ 1], which contributes to a deeper understanding of the perioperative outcomes of patients with stage II/IV non-small-cell lung cancer (NSCLC) with tumour resection after neoadjuvant immunotherapy, alone or as part of multimodal treatment. For this purpose, 37 patients were identified from 2017 to 2019 and retrospectively evaluated in 2 large-volume institutions. Of these patients, 49% were stage IIIB and IV, 46% received immunotherapy alone and 54% had a combination of chemo- and/or radiotherapy. From a surgical point of view, 16% of the cases were treated using a minimally invasive approach. Furthermore, slightly more than a half had a lobectomy (half of which were extended procedures) and 11 underwent a pneumonectomy (of these, 5 had extra pleural procedures). There were no 90-day deaths, and postoperative complications occurred in 27% of the...
9 August 2022 in CardioVascular and Interventional Radiology